

## First reports of adverse drug reactions

© Springer Nature Switzerland AG 2019

Table 1 contains an overview of first published case reports of adverse drug reactions identified in the international literature in recent weeks by *Reactions Weekly*, the Adis drug safety newsletter. *Reactions Weekly* provides summaries of

adverse drug reaction news sourced from journals, scientific meetings, media releases, regulatory agency websites, and bulletins from the National Centers that participate in the WHO International Drug Monitoring Programme.

**Table 1** First published reports of adverse drug reactions recently identified by *Reactions Weekly*

Drug and adverse reaction	References
Antimicrobial peptide LL-37: verrucous papules and erythematous plaques on the trunk and extremities, and lichenoid dermatitis	Dolkar T, Trinidad CM, Nelson KC, et al. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: a detailed examination of the clinicopathologic features. <i>J Cutan Pathol.</i> 2018;45(7):539–44. <a href="https://doi.org/10.1111/cup.13262">https://doi.org/10.1111/cup.13262</a>
Hypromellose: chronic inflammatory granulomata due to carbopol 980 excipient	Areaux RG, Maltry AC. Chronic inflammatory granulomata after use of GenTeal gel during strabismus surgery. <i>J AAPOS.</i> 2018;22(6):473–5. <a href="https://doi.org/10.1016/j.jaapos.2018.04.015">https://doi.org/10.1016/j.jaapos.2018.04.015</a>
Indoximod: parkinsonism (serious)	Floyd M, Osta BE, Tang S-C. First report of parkinsonism associated with indoximod, an immune-modulating agent. <i>J Glob Oncol.</i> 2018;(4):1–2. <a href="https://doi.org/10.1200/jgo.2016.007492">https://doi.org/10.1200/jgo.2016.007492</a>
Radium 223 chloride: osteonecrosis of the jaw (serious)	Herlofson BB, Kjølle GK, Westgaard KL, et al. Osteonecrosis of the jaw in a patient with bone metastatic prostate cancer after long-term bisphosphonate treatment with severe deterioration following radium-223. <i>Clin Genitourin Cancer.</i> 2018;16(5):328–31. <a href="https://doi.org/10.1016/j.clgc.2018.05.003">https://doi.org/10.1016/j.clgc.2018.05.003</a>
Tandospirone: rhabdomyolysis (serious)	Miyazaki K, Otaka M, Yasui-Furukori N. Tandospirone-induced rhabdomyolysis. <i>Clin Neuropharmacol.</i> 2018;41(6):216–7. <a href="https://doi.org/10.1097/wnf.0000000000000303">https://doi.org/10.1097/wnf.0000000000000303</a>

An event is serious (US FDA MedWatch definition) when the patient outcome is death, life threatening, hospitalization, disability, congenital anomaly or requires intervention to prevent permanent impairment or damage